This is a remarkable honor, as the College of Fellows is comprised of only the top two percent of the most accomplished and distinguished professors, researchers, innovators, and entrepreneurs in the fields of #medical and #biologicalengineering. Read More >>>
Fascinating presentation by our R&D Director Lyora Aharonov at the Weizman Institute of Science! Great job👏 Read More >>>
Amazing #volunteerwork of NurExone Biologic’s team members as part of the global Good Deeds Day! 👏 👏 👏 Our team members Lior Shaltiel, PhD, Lyora Aharonov, Kineret Taler, Lulu Fahoum and Saray Tabak, Ph.D was assigned to the Israeli association “giving with love” (Notnim Bea’ava, Haifa), who distribute food packages
Yesterday I had the opportunity to present NurExone Biologic‘s technology at the ILANIT/FISEB Conference, during a session called “Latest advances in extracellular vesicles: from bench to bedside”. It is amazing to see the growing interest in EVs both in academia an in the Biomed Industry, and this year for the first time
Yesterday, our Chief scientific advisor Prof. Shulamit Levenberg presented our company at the The Peres Center for Peace and Innovation in an event called “Women Creating Scientific Innovations”. NurExone Biologic is one of the three spin-out companies that came out of the Levenberg Lab together with Aleph Farms and Nanosynex.
Great trip to Canada and New York for NurExone Biologic‘s team! 👏🏻 One of the challenges as a company that operates in Israel and is publicly traded in Canada is to get to know the local market and have the players get to know us! Thanks team for this huge leap
Today is the OurCrowd Global Investor Summit, and it is an incredible event. The conference is sold out, with over 10,000 attendees in the heart of Jerusalem, Israel. #investors , #institutionalinvestors , #familyoffices #vc, from all over the world have come to meet Israeli entrepreneurs and companies of the #israelitech eco-system. As a #Canadian financier, I like to speak with Israeli entrepreneurs
NurExone Biologic is developing a revolutionary biological Extracellular Vesicles (EVs)-based technology drug platform to provide functional recovery from damage in the central nervous system (CNS). According to the National Cancer Institute (NCI), exosomes which look like tiny sacs approximately 30 to 150 nm in diameter are formed inside a cell and contain
The company is developing treatment for full or partial reversal of paralysis and improving the lives of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequences. NurExone’s technology is being used to develop treatment of various conditions, including spinal cord
NurExone Biologic Ltd., an Israeli biopharmaceutical company aiming to revolutionize the treatment of spinal cord injury (SCI), is leveraging its proprietary technologies into a platform technology company with a potentially diverse portfolio of novel, cutting-edge therapies for several CNS traumatic indications. Read More …
